&w=3840&q=100)
Breakthrough in hunt for AIDS treatment: Scientists develop new mRNA technique for permanent HIV treatment
Scientists have seemed to have found a breakthrough in curing the deadly HIV AIDS, which will force the virus out of blood cells.
The possible cure tackles the HIV's ability to conceal itself in white blood cells, capable of reactivation, rendering any treatment or drug useless to deal with the virus.
A paper published in Nature Communications says that scientists at the Peter Doherty Institute for Infection and Immunity in Melbourne have tapped into mRNA technology to locate the AIDS virus and thereby fully clear it from an infected body.
STORY CONTINUES BELOW THIS AD
For the first time, researchers have demonstrated that mRNA can be delivered into the cells harbouring hidden HIV by encasing it in a specially designed microscopic fat bubble. Once inside, the mRNA prompts the cells to expose the dormant virus.
Dr Paula Cevaal, the co-author of the study, said the employment of mRNA technology in the type of white blood cell that is home to HIV was earlier thought to be 'impossible' as those cells did not take up the fat bubbles, or lipid nanoparticles (LNPs) that are used to carry them.
Our hope is that this new nanoparticle design could be a new pathway to an HIV cure,' Cevaal said, adding that her team has developed a new type of LNP that those cells will accept, known as LNP X.
However, more research is required to determine whether merely exposing the virus is sufficient for the immune system to eliminate it, or if this approach needs to be paired with other treatments to fully eradicate HIV from the body.
'In the field of biomedicine, many things eventually don't make it into the clinic – that is the unfortunate truth; I don't want to paint a prettier picture than what is the reality. But in terms of specifically the field of HIV cure, we have never seen anything close to as good as what we are seeing, in terms of how well we are able to reveal this virus,' Cevaal said.
STORY CONTINUES BELOW THIS AD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
2 hours ago
- Hindustan Times
No change in blood donation rules for transpersons: Govt
NEW DELHI The Supreme Court building in New Delhi. (HT Photo) The Union government has told the Supreme Court that there is no need to revise the existing blood transfusion policy prohibiting donation from transgender persons, men having sex with men (MSM) and women sex workers, underlining that these groups continue to present a statistically higher risk of HIV and other transfusion-transmitted infections. 'Allowing blood donations from individuals statistically linked with a higher prevalence of TTIs (transfusion-transmitted infections) would proportionately increase systemic risks and undermine the integrity and reliability of the national blood supply chain… No modification or relaxation of the guidelines is warranted at this time,' said an affidavit by the ministry of health and family welfare filed before a bench led by justice Surya Kant. Maintaining that the deferment of individuals belonging to high-risk categories is both 'reasonable and essential', the affidavit added: 'These guidelines are firmly rooted in globally accepted scientific research, established public health principles, and robust epidemiological evidence. Any dilution or relaxation of these standards would pose a serious risk to the safety and integrity of the national blood supply.' The affidavit was filed in response to the court's oral suggestion in May that the policy be reconsidered in light of medical advancements and evolving global practices. Acting on the court's direction, the Directorate General of Health Services set up an expert committee, which met on May 29 and concluded that no change was warranted in the 2017 Guidelines for Blood Donor Selection and Referral. The expert panel highlighted that even the most advanced testing technologies cannot offer absolute assurance of detecting infections during the 'window period' when diseases like HIV remain undetectable. In such circumstances, exclusion of high-risk groups was described as a 'prudent, precautionary, and evidence-based measure' aligned with international standards. 'Notwithstanding the availability of modern testing technologies, no diagnostic test can offer a 100% guarantee of detecting all infections, particularly during the 'window period,' wherein certain infections may remain undetectable,' stated the affidavit, adding that due to such inherent limitations, the exclusion of high-risk categories continues to be a 'prudent, precautionary, and evidence-based measure'. Pointing to epidemiology, the Centre said the challenged clauses rest on data, not stigma. 'Multiple international research studies have consistently highlighted a significantly high prevalence of HIV and other sexually transmitted infections among transgender persons, particularly transgender women… Accordingly, the deferment… is rooted in established epidemiological data and public health evidence, which reflect a higher incidence of TTIs, notably HIV, within such population groups,' it said. The government also noted that while some Western countries have lifted restrictions on certain donor categories, many Asian neighbours, including Sri Lanka, Thailand, Indonesia, the Philippines, Malaysia, Singapore and China, continue to uphold similar bans. India, it said, must base its policies on its own epidemiological profile, health care infrastructure and diagnostic capacities. Invoking constitutional obligations, the Centre framed the policy as a precaution the Constitution demands. 'The continued adherence to the precautionary principle in matters relating to blood safety is not only justified but also constitutionally mandated under the State's obligation to protect public health, as enshrined in Article 47 of the Constitution of India,' the affidavit asserted. The affidavit comes after the Supreme Court, during a hearing on May 14, questioned the rationale of branding entire communities as 'risky' donors. The bench had asked: 'Are we going to brand all transgenders as risky and stigmatise them? You cannot say that all transgenders are indulging in sexual activity.' The court had observed that transgenders already face severe prejudice and warned against creating 'a segregated group' that would deepen stigma. The petitions, including one filed by Manipur-based transgender activist Thangjam Santa Singh in 2021, have challenged some relevant clauses of the 2017 guidelines, arguing that they are unconstitutional as they discriminate on the basis of gender identity and sexual orientation. The plea asserts that the exclusions perpetuate stereotypes and violate the right to equality under Articles 14 and 15 of the Constitution.
The Hindu
2 days ago
- The Hindu
Study finds people in poorer nations might be paying more for same essential drugs, compared to rich countries
An analysis of prices of about 550 medicines across 72 countries in 2022 has found that people in low- and middle-income nations could be paying more compared to wealthier ones for the same essential drugs, thereby placing a disproportionate cost burden on patients in poorer nations. Researchers from the US' Brown University and London School of Economics and Political Science (UK) said that 'nominal price' or the price stated on a medicine was higher in richer countries. However, upon accounting for purchasing power in the local currency, actual prices were found to be higher in poorer countries. They estimated that the typical number of doses of essential medicines consumed per person in 2022 was highest in Europe (634) and lowest in Southeast Asia (143). The results, published in The Journal of the American Medical Association (JAMA) Health Forum, indicate that poorer countries face a higher burden of medicine costs, the authors said. For example, they added, while prices in India were low in nominal terms (fourth lowest of the 72 markets analysed), the prices were toward the middle of the range after purchasing power was taken into account (29th of 72 markets). They also noted that while nominal prices were the lowest in Pakistan, actual prices were closer to those in Germany upon accounting for purchasing power. Drug prices were also found to vary between countries by disease that the drug is used for treating. For most countries, the highest-priced drugs tended to be those used for treating mental and behavioural disorders and cardiovascular conditions, while the lowest-priced products were those to treat hepatitis B and C, the authors said. The team further looked at eight essential medicines, used for treating major causes of death and disability the world over, including the antibiotic 'amoxicillin' (used to treat community-acquired pneumonia), escitalopram (depression) and ibuprofen (pain). Affordability for the drugs was assessed based on number of days' minimum wages required for purchasing the drugs. People in India would need to work the most number of days at minimum wage -- about 10 days -- to pay for a monthly regimen of tenofovir disoproxil (used for treating Hepatitis B and HIV/AIDS) out of pocket, the team said. Affordability was found to be typically highest in Europe and the Western Pacific, and lowest in Africa and southeast Asia. "Our results show that while drugs may have a lower nominal price in low- and middle-income countries, they may still be less affordable when considering the relative purchasing power of local currencies," the authors wrote. "This indicates that some poorer countries face a higher burden of medication costs," they added.
Time of India
3 days ago
- Time of India
Cong: Tripura's healthcare ‘collapsed' under BJP
Agartala: Criticising the BJP-led govt in Tripura, the opposition Congress alleged the state's healthcare system has 'completely collapsed' even as chief minister Manik Saha is himself a doctor. Congress spokesperson Prabir Chakraborty on Saturday alleged that instead of delivering quality healthcare, the state has witnessed corruption and medical negligence, leading to deaths. Reports from both govt and independent agencies have 'punctured' the much-publicised claim of a 'health revolution', he claimed. According to a recent report by the Union ministry of health and family welfare, Tripura ranked first among northeastern states in malaria and chikungunya cases in 2024-25, despite having only 44 lakh population as compared to Assam's over three crore, Chakraborty said. In 2023, the state recorded 22,412 malaria cases, nearly half of the northeast's total, while chikungunya cases rose from 1,557 in 2023 to 2,452 in Dec 2024, he said. Chakraborty said the report further revealed a disturbing rise in HIV cases. PTI Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
